Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.01.2015 | main topic | Ausgabe 1-2/2015

Wiener Medizinische Wochenschrift 1-2/2015

Anti-TNFs in axial spondyloarthritis

Wiener Medizinische Wochenschrift > Ausgabe 1-2/2015
MD Roland Kocijan, MD Christian Muschitz, MD Jürgen Rech


Since there is no evidence regarding the efficacy of conventional synthetic disease modifying anti-rheumatic drugs in the improvement of axial spondyloarthritis (SpA), anti-tumor necrosis factors (anti-TNFs) are recommended if nonsteroidal anti-inflammatory drugs fail, or in case of high disease activity. Anti-TNFs show encouraging data regarding pain reduction, improved mobility and quality of life in both ankylosing spondylitis and non-radiographic axial spondyloarthritis. However, withdrawal of anti-TNF therapy leads to relapse of disease activity in SpA. Moreover, osteoproliferation does not seem to be influenced by anti-TNFs.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Über diesen Artikel

Weitere Artikel der Ausgabe 1-2/2015

Wiener Medizinische Wochenschrift 1-2/2015 Zur Ausgabe


Biologika bei SLE